High Vitamin K Status is Prospectively Associated with Decreased Left Ventricular Mass in Women: The Hoorn Study

Joline W.J. Beulens
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

Elisa Dal Canto (✉️ e.dalcanto@amsterdamumc.nl)
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

Coen D.A. Stehouwer
Maastricht UMC+: Maastricht Universitair Medisch Centrum+

Roger J.M.W. Rennenberg
Maastricht University Hospital: Maastricht Universitair Medisch Centrum+

Petra J.M Elders
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

Adriana Johanne van Ballegooijen
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

Research

Keywords: vitamin K status, echocardiograph, matrix gla protein, vascular calcification

DOI: https://doi.org/10.21203/rs.3.rs-280922/v1

License: ☺️  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Vitamin K is associated with reduced cardiovascular disease risk such as heart failure, possibly by carboxylation of matrix-gla protein (MGP), a potent inhibitor of vascular calcification. The relationship of vitamin K intake or status with cardiac structure and function is largely unknown. Therefore this study aims to investigate the prospective association of vitamin K status and intake with echocardiographic measures.

**Methods:** This study included 427 participants from the Hoorn Study, a population-based cohort. Vitamin K status was assessed at baseline by plasma desphospho-uncarboxylated MGP (dp-ucMGP) with higher concentrations reflecting lower vitamin K status. Vitamin K intake was assessed at baseline with a validated food-frequency questionnaire. Echocardiography was performed at baseline and after 7.6 years follow-up. We used linear regression for the association of vitamin K status and intake with left ventricular ejection fraction (LVEF), left atrial volume index (LAVI) and left ventricular mass index (LVMI), adjusted for potential confounders.

**Results:** The mean age was 66.8±6.1 years (51% were male). A high vitamin K status was prospectively associated with decreased LVMI -5.0 (-10.5;0.4) g/m².7 for the highest quartile compared to the lowest in women (P-interaction sex=0.07). No association was found in men. Vitamin K status was not associated with LVEF or LAVI. Intakes of vitamin K were not associated with any of the echocardiographic measures.

**Conclusions:** This study indicates that a high vitamin K status is associated with decreased LVMI only in women. These results extend previous findings for a role of vitamin K status to decrease heart failure risk.

Introduction

Vitamin K is a fat-soluble vitamin occurring in two biologically active forms; phylloquinone (vitamin K₁) and menaquinones (vitamin K₂) (1). Vitamin K₁ is mainly derived from green leafy vegetables, while vitamin K₂ mainly occur in fermented animal products like cheese and meat. Vitamin K functions a co-factor for carboxylation (activation) of gla-proteins.

Matrix-gla protein (MGP) is a vitamin-K dependent protein and a potent inhibitor of vascular calcification (2). Luo et al. showed that MGP knock-out mice died within 6–8 weeks due to massive calcification (2). In humans, the Keutel syndrome, resulting from a loss-of-function mutation, is associated with vascular calcification (3). Use of vitamin K antagonists is also associated with increased vascular calcification in animal models (4, 5). Similarly, a high vitamin K intake has been associated with a reduced risk of vascular calcification and cardiovascular diseases (CVD) in prospective population-based cohorts (6). Finally, animal and human intervention studies showed that vitamin K supplementation may reduce vascular calcification by carboxylating MGP (7–9).

Uncarboxylated MGP, as measured by desphospho-uncarboxylated MGP (dp-ucMGP) has been suggested as a marker for vitamin K status, with high concentrations indicating a low vitamin K status (7). High
concentrations of dp-ucMGP have been associated with increased vascular calcification (10) and risk of cardiovascular outcomes (11, 12), although the results are inconsistent (13, 14). Dalmeijer et al. showed that high concentrations of dp-ucMGP were associated with increased risk of CVD and especially with heart failure (HF) (10).

Studies on the relationship of vitamin K intake or status with cardiac structure and function are, however, scarce. In patients with HF, high dp-ucMGP concentrations were associated with the degree of left ventricular (LV) systolic dysfunction (15) and with mortality (16). Conversely, a high vitamin K intake has been associated with a reduced HF mortality (17). Finally, three cross-sectional studies investigated the relation of vitamin K status with cardiac function. Among patients with aortic stenosis, high concentrations of dp-ucMGP were associated with reduced left ventricular ejection fraction (LVEF) (18). Hashmath et al. showed that patients with HF had a lower vitamin K status than controls (19). Finally, Wei et al. showed that high dp-ucMGP concentrations were associated with LV diastolic dysfunction at echocardiography (20). However, prospective studies investigating the relationship between vitamin K status and intake with cardiac structure and function are currently lacking.

Therefore, the aim of this study is to investigate the association of vitamin K status and vitamin K intake with cardiac structure and function in a prospective, population-based cohort, the Hoorn Study.

Materials/ Subjects And Methods

Study population

The Hoorn Study is a prospective observational cohort study in Dutch older adults (N = 2,484) initiated in 1989. Detailed information on the research design, procedures and methods, has been published previously (21). We included 831 participants of the Hoorn Study, who participated in extensive cardiovascular examinations between 2000–2001, considered as baseline. This group was oversampled for individuals with impaired glucose tolerance (IGT) and type 2 diabetes mellitus to enable investigation of effect modification by glucose tolerance status (21). After 8 years of follow-up (2007–2009), a repeated echocardiogram was obtained in 438 participants (details about loss to follow up are displayed in Additional File 1).

Participants with unsatisfactory echocardiograms at follow-up, and with missing data on vitamin K status or intake for the respective analyses were excluded, resulting in 405 participants for analyses on vitamin K status and 427 participants for analyses on intake (Additional File 1). We did not have complete data on all three echocardiographic outcomes, which resulted in different analytic samples for each outcome measure with N = 301 for LVEF, N = 309 for LV mass index (LVMI) and of N = 324 for left atrial volume index (LAVI) for vitamin K status and of N = 312 for LVEF, N = 324 for LVMI and N = 335 for LAVI for vitamin K intake. All participants provided written informed consent and the local ethics committee of the VU University Medical Center approved the study.

Vitamin K status
Study personnel collected morning blood samples in a 8–12 h fasted state. Samples were stored at -80°C until assessment of biochemical measures. Vitamin K status was measured at baseline by plasma dp-ucMGP concentrations using a sandwich ELISA with the capture of antibody directed against the nonphosphorylated MGP sequence 3 to 15 (mAb-dpMGP; VitaK BV, Maastricht, the Netherlands). High levels of dp-ucMGP reflect a low vitamin K status (7). The interassay coefficient of variation was 9.9%.

**Vitamin K intake**

At baseline, dietary intake was assessed using a self-administered validated food frequency questionnaire (FFQ) (22), allowing the estimation of the average daily intake of 178 foods over 77 main food categories in the year preceding enrolment. The 1993 Dutch food consumption table (NEVO) was used to calculate energy and nutrient intakes (23). This table does not include information on vitamin K content of all food products. Therefore, the vitamin K1, short chain vitamin K2 and long chain vitamin K2 concentrations in a series of Dutch foods were assessed at the R&D Group VitaK, Maastricht University. These values were supplemented with earlier analyses by Schurgers and Vermeer and the U.S. food composition database (24). Finally the vitamin K database was completed by estimating vitamin K1 and vitamin K2 content through recipes and ingredient information. The relative validity of the FFQ for vitamin K, with this database, has been assessed against 12 monthly 24-hour recalls among 121 men and women (24). The relative validity for energy adjusted vitamin K1, vitamin K2, short- and long-chain vitamin K2 intake were 0.34, 0.56, 0.32 and 0.66, respectively.

**Echocardiography**

Experienced ultrasound analysts performed the echocardiographic imaging at baseline (2000/2001) and at follow-up (2007/2009), using the HP SONOS 5500 echocardiography system (2–4 MHz transducer, Andover, MA, USA) according to a standardized protocol consisting of two-dimensional, M-mode and pulsed wave Doppler assessments (25). All echocardiograms were evaluated afterwards by a senior cardiologist.

Cardiac structure was measured by LVMI, which was calculated from linear dimensions by using the American Society of Echocardiography recommended formula and indexed to height^{2.7}. (25). LV systolic function was determined by LVEF (%), which was calculated using the modified Simpson's rule (25). As a marker of LV diastolic function the left atrial volume was measured at end-systole and indexed by body surface area resulting in LAVI (mL/m²) (26).

**Covariates**

At baseline, participants were asked to fill out questionnaires about lifestyle factors (physical activity), medical history, medication use and smoking status (never/former/current smokers) (21). Dietary intake of other nutrients than vitamin K was based on self-report using by the same validated FFQ (22). Educational level was self-reported based on the highest ascertainment, and stratified according to three categories: 1) low (no/primary education); 2) middle (secondary education); 3 high (tertiary education). Information on prior and incident CVD was based on self-report in combination with medical records.
Weight was divided by height squared to calculate body mass index (BMI, kg/m²). Blood pressure (mmHg) was measured twice at the left upper arm in a sitting position using an oscillometric device and averaged (Collin Press-Mate, BP-8800). Glucose tolerance status (NGT, IGT or diabetes) was determined using the results of an oral glucose tolerance test combined with the fasting glucose levels, according to the WHO 1999 criteria (27). The estimated glomerular filtration rate (eGFR, mL/min) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2009) Eq. (28). Plasma BNP was determined in spare frozen EDTA samples, which had been stored at −80°C for 4 years. B-type natriuretic peptide was determined in pmol/L (equivalent to 3.5 pg/mL) using an immunoradiometric assay kit (Shionoria, Osaka, Japan) with inter- and intra-assay variability coefficients in the relevant range <10% (29).

**Statistical analyses**

All analyses were performed using SPSS Statistics, version 22.0 and R software version 3.1.1 (R-Foundation Statistical Computing). Two-sided P-values of <0.05 were considered statistically significant. Vitamin K status and energy-adjusted intakes of all forms of vitamin K were categorized into quartiles. For vitamin K status the quartile with the highest dp-ucMGP concentrations and thus the lowest vitamin K status was used as the reference category. For quartiles of vitamin K intake, the lowest quartile was used as the reference category. Baseline characteristics were summarized by quartiles of vitamin K status and intake.

Missing values for any covariates were present in 279 and 301 participants respectively for analyses on vitamin K status and intake, ranging from 0.2% for HbA1c to 2.9% for presence of CVD, and only BNP had 20.1% missing data. Multiple imputations were used combining ten iterations into one imputation model. The longitudinal association of vitamin K status and intake with LVEF, LVMI and LAVI at follow-up were estimated using linear regression models adjusted for follow-up duration, glucose tolerance status and baseline value of the echocardiographic outcome. We additionally adjusted for confounders in a stepwise manner. Model 1 additionally adjusted for age and sex. Model 2 adjusted for BMI, smoking, physical activity, systolic blood pressure, presence of CVD, cholesterol, HbA1c and education. For vitamin K intake, we additionally adjusted for dietary factors associated with vitamin K intake: total energy intake and energy-adjusted intakes of protein, saturated fat, fiber, calcium and vitamin C. The median level of vitamin K status or intake in each quartile was included as a continuous factor in the analysis to assess the P-trend over the categories.

We also included the quadratic term of continuous vitamin K status or intake along with the continuous term to assess evidence for deviation of a linear relationship. In case this quadratic term was significant, we used spline regression to explore the functional forms of the prospective associations between continuous vitamin K status or intake and echocardiographic measures.

Sex, glucose tolerance status and prior CVD were assessed as effect modifiers by including interaction terms in the fully adjusted models. Wald tests were used to assess whether the models with the
interaction terms differed significantly from the initial models. In case interaction was present \( (P < 0.10) \), we stratified the results (30).

Sensitivity analyses were conducted by excluding cases with incident CVD during follow-up and by adjusting the final model for changes over time in smoking, physical activity and BMI. Finally, to investigate selection bias due to loss to follow-up, baseline characteristics of participants and dropouts were compared and a sensitivity analysis was performed using inverse-probability weighting for the longitudinal models.

## Results

### Baseline characteristics

Our study population for vitamin K status of 405 participants had a mean age of 66.8±6.1 years and 50.9% was male. At baseline, participants with a higher vitamin K status were younger, more often male, more often current smokers, had a lower systolic blood pressure and lower BMI than those with a low vitamin K status (Table 1). Among the 427 participants for vitamin K intake analyses, those with a high vitamin K intake were younger, less often male, lower educated, more physically active and had higher intakes of protein, fiber, vitamin C and calcium than those with a low vitamin K intake (Additional File 2). Those excluded in this study were older, had lower vitamin K status, more comorbidities and a slightly worse cardiac structure and function (Additional File 3).

Table 1

Baseline characteristics of 405 participants stratified by quartiles of vitamin K status
| Quartiles of dp-ucMGP (pmol/L) | Dp-ucMGP (pmol/l) (min-max) | Total population | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
|---|---|---|---|---|---|---|
| | | 578±410 | 680-4608 | 597±56 | 366-507 | 258±70 |
| | | 97-4608 | | 1047±581 | 508-697 | 432±41 |
| | | | | 103 | | 405 |
| | | | | 66.8±6.1 | | 102 |
| N | | | | 67.7±4.9 | | 103 |
| Age (years) | 405 | 98 | 102 | | | |
| Male sex (%) | | | | 47.1 | | 27.2 |
| High education (%) | | | | 59.2 | | 22.5 |
| Current smoking (%) | | | | 66.2±6.1 | | 22.5 |
| Physical activity (h/week) | | | | 24.0±19.8 | | 17.6 |
| Type 2 diabetes (%) | | | | 22.2±15.7 | | |
| Previous CVD (%) | | | | 27.5 | | |
| Systolic blood pressure (mmHg) | | | | 34.3 | | |
| Total cholesterol (mmol/l) | | | | 63.7±10.2 | | |
| HDL cholesterol (mmol/l) | | | | 60.6±8.7 | | |
| HbA1c (%) | | | | 61.8±10.5 | | |
| BMI (kg/m²) | | | | 64.1±9.5 | | |
| eGFR (ml/min/1.73m²) | | | | 68.1±10.3 | | |
| Echocardiographic measures | | | | | | |
| LVMI (g/m².7) | 40.3±11.3 | 42.9±12.7 | 41.0±11.4 | 39.2±9.1 | 38.5±11.4 |
| Ejection fraction (%) | 62.0±8.0 | 63.3±8.0 | 60.8±8.8 | 62.6±7.6 | 61.4±7.3 |
| LAVI (mL/m²) | 24.7±7.9 | 26.4±11.1 | 25.0±7.2 | 22.9±5.7 | 24.5±6.3 |
| BNP (pg/ml) | 0.5 [0.2, 0.9] | 0.6 [0.3, 0.9] | 0.7 [0.4, 1.1] | 0.3 [0.2, 0.7] | 0.4 [0.2, 0.7] |
| Dietary intake | | | | | | |
| Energy (kcal/day) | 1980±508 | 1875±489 | 2016±490 | 2056±512 | 1970±528 |
| Saturated fat (g/day) | 31.0±6.4 | 31.2±6.0 | 30.4±7.2 | 32.3±7.0 | 30.4±5.0 |
|                                | 1         | 2         | 3         | 4         | 5         |
|--------------------------------|-----------|-----------|-----------|-----------|-----------|
| Protein (g/day) \(^1\)         | 73.3±11.1 | 71.3±10.4 | 72.2±10.8 | 75.0±10.0 | 74.8±12.6 |
| Fiber (g/day) \(^1\)           | 24.3±4.7  | 23.2±4.9  | 24.6±4.4  | 24.0±4.5  | 25.3±4.7  |
| Vitamin C (mg/day) \(^1\)      | 107±42.1  | 107±46.9  | 109±41.4  | 105±36.4  | 109±43.8  |
| Calcium (mg/day) \(^1\)        | 1058±297  | 1028±281  | 1073±281  | 1065±293  | 1065±333  |
| Alcohol (g/day)                 | 7.2 [1.1-18.0] | 5.9 [0.7-22.7] | 7.5 [1.1-18.2] | 8.2 [1.7-18.1] | 6.9 [1.0-12.1] |
| Vitamin K\(_1\) (mg/day) \(^1\) | 185±75.8  | 172±72.2  | 184±83.1  | 192±69.8  | 189±76.9  |
| Vitamin K\(_2\) (mg/day) \(^1\) | 35.4±13.6 | 35.0±12.1 | 33.2±13.1 | 35.6±12.2 | 37.7±16.4 |
| Total vitamin K (mg/day) \(^1\) | 220±77.9  | 207±74.3  | 218±85.0  | 227±71.2  | 227±79.7  |
| Short-chain vit K\(_2\) (mg/day) \(^1\) | 22.6±7.5 | 22.6±6.8  | 21.1±7.6  | 23.9±7.1  | 23.0±8.4  |
| Long-chain vit K\(_2\) (mg/day) \(^1\) | 12.2±10.5 | 11.8±9.5  | 11.6±8.7  | 11.2±9.6  | 14.1±13.3 |

\(^1\) Energy-adjusted intakes
Values represent mean values and standard deviation, percentages or median (interquartile range)

Table 2

Prospective association between vitamin K status and echocardiographic measurements in 405 participants
|                      | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P-trend |
|----------------------|------------|------------|------------|------------|---------|
| **LVMI (g/m^2.7)^1** |            |            |            |            |         |
| Men N=206            | 45.2±11.7  | 43.6±13.3  | 40.7±10.4  | 40.9±9.2   |         |
| Model 1              | Ref (0.0)  | 2.1 (-2.9; 7.1) | -0.7 (-5.4; 4.0) | -1.8 (-6.6; 3.0) | 0.353   |
| Model 2              | Ref (0.0)  | 1.8 (-3.1; 6.8) | -0.5 (-5.2; -4.1) | -1.3 (-6.4; 3.7) | 0.611   |
| Women N=199          | 46.7±15.6  | 45.1±12.5  | 38.9±7.7   | 35.6±9.3   |         |
| Model 1              | Ref (0.0)  | -0.3 (-4.8; 4.2) | -7.2 (-11.9; -2.6) | -6.5 (-11.2; -1.8) | <0.001  |
| Model 2              | Ref (0.0)  | 0.4 (-2.9; 3.7) | -6.8 (-11.8; -1.8) | -5.0 (-10.5; 0.4) | <0.001  |
| **LVEF (%)^1**       | 52.3±10.2  | 52.0±11.2  | 53.3±9.8   | 53.4±9.2   |         |
| Model 1              | Ref (0.0)  | 1.3 (-1.9; 4.4) | 1.0 (-2.1; 4.1) | 1.3 (-1.9; 4.5) | 0.48    |
| Model 2              | Ref (0.0)  | 1.1 (-2.1; 4.3) | 0.8 (-2.4; 3.9) | 1.1 (-2.4; 4.5) | 0.61    |
| **LAVI (mL/m^2)^1**  | 28.0±18.0  | 26.0±10.6  | 25.2±10.1  | 24.0±9.4   |         |
| Model 1              | Ref (0.0)  | -0.8 (-4.0; 2.3) | 0.50 (-2.6; 3.6) | -1.8 (-5.1; 1.4) | 0.43    |
| Model 2              | Ref (0.0)  | -0.4 (-3.5; 2.6) | 0.9 (-2.2; 3.9) | -0.1 (-3.3; 3.3) | 0.79    |

^1 Mean echocardiographic measures at follow-up

P-for interaction vitamin K status and LVMI by sex=0.07

Abbreviations: LVMI: left ventricle mass index; LVEF left ventricular ejection fraction; LAVI: left atrium volume index

Quartile 1: reflects a low vitamin K status (high dp-ucMGP)

Model 1: Adjusted for baseline echo value (i.e. LVMI at follow-up adjusted for baseline LVMI), follow-up duration, age, sex and glycemic status

Model 2: Adjusted for model 1 and physical activity, smoking, BMI, systolic blood pressure, total cholesterol, HbA1c, education, prior CVD, BNP and eGFR

### 3.1 Vitamin K status

Mean vitamin K status was 578±410 pmol/L and showed a distribution somewhat skewed to the right. The mean follow-up time was 7.6 years.

In the linear regression models, including interaction terms for sex, glycemic status or previous CVD showed only evidence of interaction between vitamin K status and sex for LVMI (P=0.07) and results are
therefore stratified by sex. Including a quadratic term in the model was statistically significant (P=0.018), suggesting evidence for a non-linear association. We observed a significant inverse relationship between vitamin K status and decreased LVMI in women for quartile 3 and 4 compared to quartile 1: -7.2(-11.9;2.6) and -6.5(-11.2;1.8), respectively, adjusted for model 1 (P-for trend<0.001). Further adjustment for model 2 slightly attenuated the association, and only quartile 3 was still significant, however the P-for trend remained strongly significant <0.001. In men, no significant association was observed. Evaluation of the continuous associations of vitamin K status with LVMI using splines revealed a similar pattern for men and women with some non-linearity in the tails (Figure 1).

Vitamin K status was not associated with either LVEF or LAVI after follow-up with estimates of -0.1 (-3.3;3.3) and 1.1 (-2.4;4.5 (mL/m²)) for quartile 4 compared to quartile 1, respectively, adjusted for model 2.

**Vitamin K intake**

Mean total vitamin K intake was 220±78 mg/day (184 mg/day vitamin K₁ and 35.5 mg/day vitamin K₂). We did not observe significant associations between any of the forms of energy-adjusted vitamin K intake at baseline and LVMI at follow-up adjusted for CVD risk factors and dietary factors (Table 3). Similarly, for LVEF we observed no significant associations for any of the forms of vitamin K intake. Although we found some evidence of a non-linear association for total vitamin K (P=0.041) and vitamin K₁ (P=0.059) with LVEF, the spline regression did not provide evidence for a clear association (Additional File 4).

In addition, we observed effect modification by presence of CVD for energy-adjusted vitamin K₂ and long-chain vitamin K₂ intake with LVEF (P-interaction<0.01), but no significant associations were observed when stratified for presence of CVD (Additional File 5). None of the forms of vitamin K intake at baseline were associated with changes in LAVI during follow-up.

Table 3

Prospective association between vitamin K intake and echocardiographic measurements in 427 participants
|                   | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P-trend |
|-------------------|-----------|-----------|-----------|-----------|---------|
| N                 | 106       | 107       | 107       | 107       |         |
| LVMI (g/m²)¹      | 42.9±12.4 | 42.1±10.9 | 40.2±10.9 | 44.4±13.0 |         |
| Total vitamin K (mg/day) | Ref (0.0) | -2.3 (-5.4; 0.8) | -3.5 (-6.7; -0.3) | -0.7 (-4.1; 2.6) | 0.54 |
| Vitamin K₁        | Ref (0.0) | 0.1 (-3.1; 3.1) | -3.8 (-7.0; -0.6) | 0.3 (-2.9; 3.6) | 0.57 |
| Vitamin K₂        | Ref (0.0) | -1.4 (-4.8; 2.1) | -0.6 (-4.2; 2.9) | -0.6 (-4.7; 3.5) | 0.88 |
| Long-chain        | Ref (0.0) | -0.1 (-3.4; 3.3) | -2.2 (-5.5; 1.1) | -0.9 (-5.0; 3.1) | 0.32 |
| Short-chain       | Ref (0.0) | -3.0 (-6.3; 0.3) | -1.7 (-5.4; 1.9) | -0.2 (-4.5; 4.1) | 0.88 |
| LVEF (%)¹         | 52.2±9.8  | 53.4±9.5  | 54.3±11.1 | 51.2±10.4 |         |
| Total vitamin K (mg/day) | Ref (0.0) | -0.3 (-3.3; 2.6) | -0.7 (-3.8; 2.3) | -1.6 (-4.4; 2.0) | 0.29 |
| Vitamin K₁        | Ref (0.0) | 1.3 (-1.7; 4.3) | 1.2 (-2.1; 4.4) | -1.2 (-4.3; 2.1) | 0.43 |
| Vitamin K₂        | Ref (0.0) | -1.3 (-4.6; 2.0) | -1.8 (-5.2; 1.5) | 2.1 (-1.9; 6.1) | 0.52 |
| Long-chain        | Ref (0.0) | -1.1 (-4.3; 2.1) | -2.6 (-5.7; 0.5) | -1.2 (-4.9; 2.6) | 0.31 |
| Short-chain       | Ref (0.0) | -0.3 (-3.5; 2.9) | 2.4 (-1.1; 5.9) | 1.2 (-3.0; 5.5) | 0.29 |
| LAVI (mL/m²)¹     | 25.3±11.7 | 26.0±11.7 | 26.6±14.0 | 26.6±12.1 |         |
| Total vitamin K (mg/day) | Ref (0.0) | -0.2 (-3.1; 2.7) | -0.6 (-3.7; 2.5) | -1.6 (-4.7; 1.5) | 0.29 |
| Vitamin K₁        | Ref (0.0) | 0.2 (-2.7; 3.2) | -1.3 (-4.3; 1.8) | -1.1 (-4.2; 2.0) | 0.33 |
| Vitamin K₂        | Ref (0.0) | 1.8 (-1.3; 5.0) | 1.8 (-1.5; 5.0) | 1.5 (-2.3; 5.3) | 0.46 |
| Long-chain        | Ref (0.0) | 2.7 (-0.2; 5.6) | 0.8 (-2.2; 3.8) | 2.1 (-1.4; 5.6) | 0.48 |
| Short-chain       | Ref (0.0) | 3.1 (0.0; 6.2) | 1.8 (-1.6; 5.2) | 0.6 (-3.3; 4.6) | 0.97 |

¹ Mean echocardiographic measures at follow-up

Abbreviations: LVMI: left ventricle mass index; LVEF: left ventricular ejection fraction; LAVI: left atrium volume index

Adjusted for baseline echocardiographic value (i.e. LVMI at follow-up is adjusted for baseline LVMI), follow-up duration, age, sex, glycemic status, physical activity, smoking, BMI, systolic blood pressure, total cholesterol, HbA1c, education, presence of CVD, BNP, eGFR, energy intake and energy-adjusted intakes of protein, saturated fat, fiber, calcium and vitamin C.
Sensitivity analyses
Excluding participants who developed CVD during follow-up (n=7) and adjusting for updated measurements of BMI, physical activity and smoking status at follow-up did not materially change our findings (Additional File 6). Adjusting for selection bias due to loss-to-follow-up using inverse probability weighting did not alter our findings as well (Additional File 6).

Discussion
This study showed that a higher vitamin K status at baseline was associated with decreased LVMI after 7.6 years of follow-up, only among women. Vitamin K status was not associated with other cardiac measures. Vitamin K intake was not associated with cardiac structure and function.

This study is the first prospective study investigating the association between vitamin K status and cardiac structure and function measures. Our results are in line with earlier cross-sectional studies showing that a low vitamin K status was associated with reduced systolic function (18) or a higher prevalence of diastolic dysfunction (20). However, in our study, a higher vitamin K status was associated with LVMI only among women and not among men, but such effect modification by sex was not investigated in earlier studies. We didn’t observe any association between vitamin K status and LVEF or LAVI.

Nevertheless, the studies that found an associations between vitamin K status and systolic or diastolic function were performed in populations with different features than those of the present study, the participants being affected by valvular diseases, HF or cardiomyopathy. Despite this association between vitamin K status and LVMI, we could not detect any clear associations between any of the forms of vitamin K intake and cardiac measures. This is inconsistent with the study by Eshak et al. showing that a higher vitamin K intake was associated with a 37% reduced risk of HF mortality after 19 years of follow-up among Japanese women (17). The inconsistent findings between both studies could be due to the relatively low sample size of our study combined with the relatively low validity of the FFQ to accurately assess vitamin K intake. For LAVI and LVEF, we observed significant non-linear associations with several forms of vitamin K intake. These associations showed slightly, but non-significantly higher LVEF and LAVI in the second and third quartile of vitamin K intake.

The underlying mechanism of vitamin K status and intake, cardiac structure and function and risk of HF may be explained by improved arterial stiffness with increased vitamin K intake and status. Vitamin K functions as a co-factor to carboxylate MGP, a potent inhibitor of vascular calcification. Animal experiments indeed showed that antagonism of vitamin K leads to vascular calcification, in particular of the medial layer of the arteries (31). Medial calcification leads to vascular stiffness (32, 33), which in turn is consistently associated with diastolic dysfunction (34). In fact, vascular stiffness may increase the systolic load on the ventricles and decrease aortic pressure during diastole, thereby increasing pulse
pressure (35). Increased pulse pressure increases myocardial oxygen demand during systole and is associated with LV hypertrophy. These changes can lead to impaired relaxation and eventually LV diastolic dysfunction and HFpEF (36). Indeed, earlier studies have shown vitamin K status to be associated with increased arterial stiffness (19, 37, 38). One possible explanation of why in our study vitamin K status affected LV structure only in women, is that women, especially after menopause, seem to be more prone to develop LV hypertrophy in response to pressure overload compared to men. Consequently, the effect of vitamin K status on arterial stiffness and cardiac overload might manifest itself only in women [32].

Strengths of this study include its prospective design and detailed phenotyping of the participants, allowing to adjust for multiple confounders. However, certain limitations need to be addressed. First, the prospective associations may be biased due to the high loss to follow-up rates in this study. Although we observed similar associations in our analyses after inverse probability weighting, we cannot exclude some selection bias. Second, for the assessment of vitamin K intake we relied on self-reported data.

Although the FFQ was validated for the assessment of vitamin K intake, the relative validity in particular for the assessment of vitamin K1 and short-chain vitamin K2 was low. In combination with the relatively small sample size, this may have yielded the study insufficiently sensitive to detect associations with vitamin K intake. Third, the definition of vitamin K status was based on a single baseline measurement of dp-ucMGP, which may only reflect short-term vitamin K status. Therefore these associations should be interpreted with caution.

Conclusions

This study showed that a high vitamin K status is associated with decreased LVMI in women. Altogether these results further extend previous associations of vitamin K status with improved cardiac structure and function and a decreased risk of HF. Future studies should investigate whether vitamin K supplementation is an effective strategy to improve cardiac structure and function and prevent HF.

Declarations

Ethics approval and consent to participate

All participants provided written informed consent and the local ethics committee of the VU University Medical Center approved the study.

Consent for publication

All participants provided informed consent for publication.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Funding

JWJ Beulens is supported by a ZonMw-VIDI grant (nr: 91718304) and AJ van Ballegooijen is supported by junior Kolff grant 16OKG02. No commercial funding was involved.

Authors' contributions

Joline W.J. Beulens, Coen D.A. Stehouwer, Roger J.M.W. Rennenberg and Adriana Johanne van Ballegooijen contributed to the study conception and design; Joline W.J. Beulens, Coen D.A. Stehouwer and Adriana Johanne van Ballegooijen contributed to data collection, assembly, analysis and interpretation of the data; Joline W.J. Beulens, Elisa Dal Canto and Adriana Johanne van Ballegooijen contributed to the revising of the manuscript; Joline W.J. Beulens, Elisa Dal Canto, Coen D.A. Stehouwer, Roger J.M.W. Rennenberg, Petra Elders and Adriana Johanne van Ballegooijen contributed to the manuscript drafting and approval of the final version of the manuscript.

Acknowledgements

The authors thank the other investigators, the staff, and the participants of the Hoorn Study participants for their valuable contributions

References

1. Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 2000;30(6):298-307.
2. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78-81.
3. Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet. 1999;21(1):142-4.
4. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood. 2004;104(10):3231-2.

5. Schurgers LJ, Spronk HM. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. Thromb Haemost. 2014;112(5):909-17.

6. Chen HG, Sheng LT, Zhang YB, Cao AL, Lai YW, Kunutsor SK, et al. Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis. Eur J Nutr. 2019;58(6):2191-205.

7. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost. 2007;98(1):120-5.

8. Shea MK, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. 2009;89(6):1799-807.

9. Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res. 2003;40(6):531-7.

10. Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Elias SG, Velthuis BK, et al. Circulating species of matrix Gla protein and the risk of vascular calcification in healthy women. Int J Cardiol. 2013;168(6):e168-70.

11. Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, et al. Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2013;36(11):3766-71.

12. van den Heuvel EG, van Schoor NM, Lips P, Magdeleyns EJ, Deeg DJ, Vermeer C, et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas. 2014;77(2):137-41.

13. Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, et al. Circulating desphospho-uncarboxylated matrix gamma-carboxyglutamate protein and the risk of coronary heart disease and stroke. J Thromb Haemost. 2014;12(7):1028-34.

14. Liu YP, Gu YM, Thijs L, Knapen MH, Salvi E, Citterio L, et al. Inactive matrix Gla protein is causally related to adverse health outcomes: a Mendelian randomization study in a Flemish population. Hypertension. 2015;65(2):463-70.

15. Ueland T, Dahl CP, Gullestad L, Aakhus S, Broch K, Skardal R, et al. Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure. Clin Sci (Lond). 2011;121(3):119-27.

16. Mayer O, Jr., Seidlerova J, Vanek J, Karnosova P, Bruthans J, Filipovsky J, et al. The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. Int J Cardiol. 2016;203:916-22.
17. Eshak ES, Iso H, Yamagishi K, Cui R, Tamakoshi A. Dietary intakes of fat soluble vitamins as predictors of mortality from heart failure in a large prospective cohort study. Nutrition. 2018;47:50-5.

18. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med. 2010;268(5):483-92.

19. Hashmath Z, Lee J, Gaddam S, Ansari B, Oldland G, Javaid K, et al. Vitamin K Status, Warfarin Use, and Arterial Stiffness in Heart Failure. Hypertension. 2019;73(2):364-70.

20. Wei FF, Trenson S, Monney P, Yang WY, Pruijm M, Zhang ZY, et al. Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS One. 2018;13(3):e0193967.

21. Rutters F, Nijpels G, Elders P, Stehouwer CDA, van der Heijden AA, Groeneveld L, et al. Cohort Profile: The Hoorn Studies. Int J Epidemiol. 2018;47(2):396-j.

22. Ocke MC, Bueno-de-Mesquita HB, Goddijn HE, Jansen A, Pols MA, van Staveren WA, et al. The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. Int J Epidemiol. 1997;26 Suppl 1:S37-48.

23. Dutch Food Composition Table 2001. Den Haag.

24. Zwakenberg SR, Engelen AIP, Dalmeijer GW, Booth SL, Vermeer C, Drijvers J, et al. Reproducibility and relative validity of a food frequency questionnaire to estimate intake of dietary phylloquinone and menaquinones. Eur J Clin Nutr. 2017;71(12):1423-8.

25. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Emane L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70.

26. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321-60.

27. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: Department of Noncommunicable Disease Surveillance. 1999.

28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

29. Boomsma F, Deinum J, van den Meiracker AH. Relationship between natriuretic peptide concentrations in plasma and posture during blood sampling. Clin Chem. 2001;47(5):963-5.

30. Greenland S. Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med. 1983;2(2):243-51.

31. Kruger T, Oelenberg S, Kaesler N, Schurgers LJ, van de Sandt AM, Boor P, et al. Warfarin induces cardiovascular damage in mice. Arterioscler Thromb Vasc Biol. 2013;33(11):2618-24.
32. Mitchell GF. Arterial Stiffness and Wave Reflection: Biomarkers of Cardiovascular Risk. Artery Res. 2009;3(2):56-64.

33. O'Rourke MF. Arterial aging: pathophysiological principles. Vasc Med. 2007;12(4):329-41.

34. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291-303.

35. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107(22):2864-9.

36. O'Rourke MF. Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance. J Am Coll Cardiol. 2001;38(3):803-5.

37. Pivin E, Ponte B, Pruijm M, Ackermann D, Guessous I, Ehret G, et al. Inactive Matrix Gla-Protein Is Associated With Arterial Stiffness in an Adult Population-Based Study. Hypertension. 2015;66(1):85-92.

38. Fain ME, Kapuku GK, Paulson WD, Williams CF, Raed A, Dong Y, et al. Inactive Matrix Gla Protein, Arterial Stiffness, and Endothelial Function in African American Hemodialysis Patients. Am J Hypertens. 2018;31(6):735-41.